RxDoctor Payments Data

Elizabeth Kellam

Physician Assistant · Spartanburg, SCNPI 1518381482

Payments from drug & device makers

$3,172in general payments, 2019–2025

Across 145 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Dexcom, Inc.$395
  • Novo Nordisk$312
  • Lilly USA, LLC$178
  • Sanofi-aventis U.S. LLC$136
  • Insulet Corporation$115
  • plus $784 from 18 others

What the payments were for

  • Food & beverage$3,172100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,172 in reported general payments places this provider in the 80th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$48,766
Medicare patients
220
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide219$295,213
MounjaroTirzepatide124$164,067
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog69$129,248
Tresiba Flextouch U-200Insulin Degludec77$121,446
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog161$120,629
Tresiba Flextouch U-100Insulin Degludec137$99,098
JardianceEmpagliflozin82$85,700
TrulicityDulaglutide68$81,764
Humalog Kwikpen U-100Insulin Lispro173$57,091
Fiasp FlextouchInsulin Aspart (Niacinamide)52$52,169
Novolog FlexpenInsulin Aspart145$51,759
FarxigaDapagliflozin Propanediol41$47,739
Lantus SolostarInsulin Glargine,hum.Rec.Anlog238$43,095
Humulin R U-500 KwikpenInsulin Regular, Human21$36,720
Xultophy 100-3.6Insulin Degludec/Liraglutide16$33,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$312$342,154285 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$178$257,803242 claims
Boehringer IngelheimJardiance$79$85,70082 claims
AstraZenecaFarxiga$27$47,73941 claims
Sanofi-aventis U.S. LLCLantus$136$8,69050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →